Featured Studies

Doctors at the National Institute on Deafness and Other Communication Disorders (NIDCD) are investigating the effectiveness of atorvastatin (a drug used to lower “bad“ cholesterol and fats such as LDL, and triglycerides, and raise “good“ cholesterol such as HDL, in the blood) at reducing the incidence of hearing loss in patients treated with cisplatin for head and neck cancer.

Doctors at the National Institute on Deafness and Other Communication Disorders (NIDCD) are investigating the effectiveness of atorvastatin (a drug used to lower “bad“ cholesterol and fats such as LDL, and triglycerides, and raise “good“ cholesterol such as HDL, in the blood) at reducing the incidence of hearing loss in patients treated with cisplatin for head and neck cancer. (En español)

The research study aims to enhance the understanding of SCD and its associated complications by investigating the relationship between the disease and specific variations of certain genes. If you have SCD, your participation in this study is highly valuable. By participating, you will undergo an evaluation and receive recommendations from a team experienced in the treatment and management of SCD.

Researchers from the National Cancer Institute at the NIH Clinical Center are currently looking for patients who have HER2-expressing endometrial cancer. The purpose of the study is to test two investigational study drugs, a vaccine that targets HER2 (AdHER2DC) and a drug that is expected to improve immune cell function (N-803). These study drugs will be used with pembrolizumab and lenvatinib which are FDA approved to treat endometrial cancer.

The risk of heart disease among African Americans is still common despite a greater understanding of the disease and better approaches to managing it. Healthy cooking and eating patterns can help reduce the risk of heart disease. But things like access to grocery stores and knowledge of good nutrition can affect these healthy patterns. Researchers at The National Institutes of Health want to see if community-based programs can help.

Myelodysplastic syndromes (MDS) are disorders caused by abnormal blood cell production, potentially leading to low cell counts and increased susceptibility to clotting and infections. Past research suggests that inflammation may trigger these abnormalities, and this study seeks to further understand and improve treatment strategies for MDS by investigating the role of inflammation in bone marrow cell development.

Join a novel research study by Dr. Gulley and his team at the National Cancer Institute (NCI) in their effort to measure pain through facial expressions and vocal communication.

People with systemic lupus erythematosus (SLE) are at risk of developing complications in their blood vessels. The risks increase for heart attacks or stroke. No medications have been effective at reducing this risk in people with lupus. Researchers at NIH are testing whether a drug (anifrolumab) can improve blood vessel function and reduce blood vessel inflammation in people with (SLE). Participants do not pay for tests, treatments, or procedures.

Doctors at the National Institutes of Health (NIH) are conducting a research study to determine the viability and safety of early initiation of oral therapy with cyclosporine and eltrombopag in patients with severe aplastic anemia (SAA).

Pharmacologic therapy with Bruton's tyrosine kinase (BTK) inhibitors is associated with an increased risk of heart problems like atrial fibrillation, bleeding, and high blood pressure (hypertension) which can lead to sudden death. There is currently no standard for cardiac screening or monitoring patients on BTK inhibitors. Researchers at the National Heart, Lung, and Blood Institute (NHLBI) are investigating the relationship between the development of heart problems in patients on BTKi as it relates to other variables.